A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza¿) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Canc
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca Pharmaceuticals, LP
Start Date
February 13, 2018
End Date
February 29, 2020
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca Pharmaceuticals, LP
Start Date
February 13, 2018
End Date
February 29, 2020